Phase 1 Start
SRZN: Phase1_Start: A First-in-human, Prospective Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes of SZN-8141 in Diabetic Macular Edema
October 30, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 30, 2026
- Company
- Surrozen Inc. (SRZN)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 1 Start
Phase1_Start: A First-in-human, Prospective Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes of SZN-8141 in Diabetic Macular Edema
- Company
- Surrozen Inc. (SRZN)